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Hyperuricemia is supposed to be an independent risk factor for kidney dysfunction in diabetic patients. 
We attempted to examine the uric acid-lowering effect and the renoprotective effect of topiroxostat, a 
selective xanthine oxidoreductase inhibitor, in patients with diabetic nephropathy and hyperuricemia in 
this pilot study. 
 
Methods 
The study design was randomized, double-blind, placebo-controlled, parallel-group study. A total of 65 
patients with hyperuricemia and diabetic nephropathy with microalbuminuria were enrolled and assigned 
to either the topiroxostat group or the placebo group. Topiroxostat (stepwise dosing from 40mg/day to 
160 mg/day) or matching placebo was administered BID for 28 weeks. The primary endpoint was a 
change in the urinary albumin-to-creatinine ratio in the first-morning-void urine sample. Secondary 
endpoints were changes in the estimated glomerular filtration rate and the serum uric acid level. 
 
Results 
At 28 weeks, there was no significant difference in the percent change from baseline in the urinary 
albumin-to-creatinine ratio between the two groups (topiroxostat: 0 vs. placebo: 17 %, p = 0.3206), but 
the changes in the estimated glomerular filtration rate (-0.2 vs. -4.0 mL/min/1.73m2, p = 0.0303) and the 
serum uric acid level (-2.94 vs. -0.20 mg/dL, p < 0.0001) were significantly different between the 
topiroxostat and placebo groups. Gouty arthritis occurred in 1 patient in the placebo group and no patients 





These findings support that diabetic nephropathy combined with hyperuricemia may be associated with 
kidney dysfunctions. Topiroxostat provides strict control of the serum uric acid level preventing decline 
of eGFR in these patients. 
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Diabetic mellitus is a major risk factor of chronic kidney disease in many countries around the world [1]. 
Moreover, diabetic kidney disease is a leading cause of end-stage renal disease[2]. It has been shown that 
combination therapy with different interventions (e.g. glycemic control, amelioration of lipid metabolism, 
and control of hypertension, especially blockage of the renin-angiotensin system) can reduce the risk for 
the progression of kidney dysfunction [3]. However, drug development for the prevention of diabetic 
nephropathy and its progression to end-stage renal disease is still not successful. It therefore remains an 
important medical challenge to find effective strategies against diabetic kidney disease. 
Meanwhile, on the basis of the well-known relationship between serum uric acid (SUA) level and renal 
function deterioration [4, 5], hyperuricemia is an independent risk factor [6] that impairs each of renal 
functions, i.e. glomerular filtration rate and albuminuria. It is pointed out that xanthine oxidoreductase 
(XOR), which converts hypoxanthine to xanthine, and xanthine to uric acid (UA), generates reactive 
oxygen species during the process of purine metabolism. Therefore, not UA excretion but UA generation 
via XOR is expected to be the therapeutic target for diseases involving inflammation and oxidative stress, 
e.g. vascular injury and renal dysfunction [7, 8]. Topiroxostat, a selective xanthine oxidoreductase 
inhibitor, is used for the management of hyperuricemia in patients with or without gout in Japan [9-11]. 
Topiroxostat not only effectively reduced SUA levels, but also had a urinary albumin-to-creatinine ratio 
(UACR) -lowering effect in hyperuricemic stage 3 chronic kidney disease patients [12]. Also, topiroxostat 
reduced the urinary albumin excretion remarkably in db/db mice as compared with febuxostat, another 
xanthine oxidoreductase inhibitor. It is suggested that this difference is associated with topiroxostat’s 
potent inhibition of the plasma xanthine oxidoreductase activity [13]. Based on these facts, we conducted 
this pilot study named “UPWARD” to investigate the UA-lowering effect and exploratory renoprotective 






This study was carried out as Phase 2a study. The study design was a 28-week, multicenter, randomized, 
double-blind, placebo-controlled, parallel-group study. We conducted the study at 12 hospitals in Japan.  
 
Inclusion and exclusion criteria 
Patients who met all of the inclusion criteria and did not meet any exclusion criteria were enrolled in the 
study. The inclusion criteria were as follows: age 20-75 years; having diabetes receiving drug treatment; 
on constant diet and/or exercise therapy for more than 8 weeks before the start of the pre-observation 
period; having clinically or pathologically diagnosed diabetic kidney disease; diagnosed with gout or 
hyperuricemia; three measurements of first-morning-void UACR in the observation period (Visit 1 or 2), 
more than two of which were >= 45 and < 300 mg/gCr; estimated glomerular filtration ratio (eGFR) was 
>= 30 mL/min/1.73m2 at Visit 1; outpatient (having no plan of hospital admission); and patients who can 
provide voluntary informed consent. The exclusion criteria were as follows: having renal diseases other 
than diabetic nephropathy (excluding nephrosclerosis); having received steroid preparations and 
immunosuppressants for the purpose of treating nephropathy within the past 10 years; having other 
systemic diseases than diabetes that induce proteinuria, e.g. collagen disease, vasculitis, amyloidosis, etc.; 
having a serum creatinine level that changed by 0.5 mg/dL or more at Visit 1 and 2; SUA level was 10.0 
mg/dL or more at Visit 1; having a history of nephrectomy or renal transplantation; acute renal injury 
within 24 weeks before the start of the pre-observation period; hepatic dysfunction e.g. aspartate 
aminotransferase (AST) or alanine aminotransferase (ALT) 100 ≥ IU/L; serious heart disease; serious 
hematologic disease; cancer; uncontrolled hypertension; uncontrolled diabetes; uncontrolled 
dyslipidemia; pregnancy; breastfeeding; onset of gouty arthritis at the start of the observation period; 
using UA-lowering agents, agents potentially affecting the SUA level and/or agents that could potentially 
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cause adverse drug interactions with the study drug for at least 2 weeks before Visit 1; judged to be 
clinically inappropriate by the investigators or sub-investigators. 
 
Randomization, intervention, and blinding 
The study plan is shown in Fig. 1. In the Pre-observation period, we screened and enrolled eligible 
subjects. The patients were assigned (2:1) to either the topiroxostat group or the placebo group at the 
central registration center. The allocation factors were as follows: (i) first-morning-void UACR is ≥ 
170mg/gCr or not; (ii) using a renin-angiotensin system inhibitor or not. Topiroxostat or matching 
placebo was administered BID at an initial dose of 40 mg/day for 4 weeks, followed by stepwise increase 
of the dose to 160 mg/day as shown in Fig. 1. Concomitant therapeutic agents for diabetes, hypertension 
(including RAS blockers), or dyslipidemia had to remain as constant as possible during the entire study 
period. SUA levels measured after administration of the study drug in each patient were concealed from 
all of the investigators and the patients throughout the study period to maintain blinding. Randomization 
was performed independently by an outsourcing agency (A2 Healthcare Corp., Japan). 
 
Efficacy endpoints 
The primary efficacy endpoint was change in UACR in the first-morning-void urine, measured twice at 
each visit, and the calculated geometric mean, from baseline to the last visit. The secondary efficacy 
endpoints were change in UACR in spot urine, eGFR and SUA levels. 
 
Safety evaluations 
To assess the safety and tolerability of study drug treatment, vital signs, 12-lead electrocardiography, and 
clinical laboratory values were observed at each visit during the study. The investigators assessed any 
adverse events (AEs) and their severity. AEs judged to be related to the investigational drug were defined 
7 
 
as adverse drug reactions (ADRs). AEs and ADRs were classified according to the system organ class and 
preferred term (MedDRA version 18.0; Japanese Maintenance Organization, Tokyo, Japan). The 
incidences of AEs and ADRs that were serious or led to discontinuation of the study were summarized by 
the number of patients and percentage in each study group. 
 
Statistical analyses 
The baseline characteristics were summarized by study group using appropriate descriptive statistics. All 
efficacy analyses at the endpoints were conducted under the full analysis set principle. For assessment of 
the UACR change, we performed logarithmic transformation of the UACR value. Adjusted average value 
and 95% confidence interval on both sides were estimated, and the obtained results are shown by inverse 
logarithmic transformation. We compared the two groups for change from baseline at the last observation 
with the analysis of covariance (ANCOVA) model. To analyze the UACR in the first-morning-void urine, 
the baseline UACR, and the use of angiotensin II receptor blockers or angiotensin-converting enzyme 
inhibitors (RAS blockers) or not, were selected as covariates. To assess UACR in spot urine, SUA, and 
eGFR, we compared the changes from baseline at the last observation with the ANCOVA model, and 
compared the results between the two groups; the covariates were each baseline value. If the data at the 
time of the last visit (28 w) was missing, it was compensated by the LOCF method. 
Safety analyses were performed on the safety population, consisting of all randomized patients who 
received at least one dose of the study drug and who had no critical GCP violations. Fisher’s exact test 
was used for comparison of the incidences between study groups. 
To determine the number of patients, we referred to a clinical study of topiroxostat for hyperuricemic 
stage 3 chronic kidney disease [12]. In this study, at 22 weeks, the mean change from baseline after 
logarithmic conversion of UACR was -0.1772 with a standard deviation of 0.2969 in the topiroxostat 
group. Assuming that topiroxostat’s effect on UACR did not diminish after 28 weeks of administration, it 
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was found that more than 32 patients are needed to compare with baseline data with α = 0.05 (two-sided 
significance level) and 1-β = 0.9. Considering a possible dropout of some patients, we set the required 
number of patients in the topiroxostat group at 40. To obtain a natural course of target patients in this 
study as comparison, we set the number of patients in the placebo group at 20. Since the main evaluation 
subject was the last observation day, we did not consider statistical multiplicity for the evaluation of each 
visit. All statistical analyses of efficacy and safety were performed independently by an outsourcing 
agency (EPS Corp., Japan) with SAS software, version 9.3 or higher (SAS Institute).  
 
Results 
Patient flow and background 
A total of 141 patients were enrolled, and 76 patients were excluded. The main reasons for withdrawal 
were UACR outside the target range (n = 56) and other unacceptable laboratory values (n = 13). Of the 
remaining 65 patients who were randomized, all patients received topiroxostat or matching placebo. Two 
patients in the topiroxostat group and 4 patients in the placebo group failed to complete the study, but no 
patients were excluded from the full analysis set (Fig. 2). 
The baseline characteristics of the randomized population are shown in Table 1. The baseline UACR was 
141.5 mg/gCr (95% confidence interval: 106.30 to 188.37 mg/gCr) in the placebo group and 114.5 
mg/gCr (95% confidence interval: 92.26 to 142.10 mg/gCr) in the topiroxostat group, without significant 
differences between the groups (two-sample t-test with logarithmic transformation values; P = 0.2416). 
The backgrounds of the two groups were similar, except for total cholesterol and low-density 
lipoprotein-cholesterol (LDL), which were significantly lower in the placebo group. 
 
Efficacy 
UACR in first-morning-void urine 
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The time course of the geometric mean of UACR in first-morning-void urine is shown in Fig. 3A. The 
percent increase in the UACR level in the first-morning-void urine from baseline to the last visit was 17% 
(95% CI: -9 to 52%) in the placebo group (n = 22) and 0% (95% CI: -17 to 20%) in the topiroxostat group 
(n = 43) with a between-group difference of -15% (95% CI: -38 to 17%) (p = 0.3206) (Fig. 4A). While 
UACR in the first-morning-void urine was upward in the placebo group, it was unchanged in the 
topiroxostat group. However, a statistically significant difference was not observed. 
The numbers of patients who had normalized UACR (< 30 mg/gCr) at the last observation were 0 (0%) in 
the placebo group and 2 (4.7%) in the topiroxostat group. 
 
UACR in spot urine 
The time course of the geometric mean of UACR in spot urine is shown in Fig. 3B. The percent increase 
in UACR in the spot urine level from baseline to the last visit was 28% (95% CI: -2 to 69%) in the 
placebo group (n = 22) and -2% (95% CI: -20 to 19%) in the topiroxostat group (n = 43) with a 
between-group difference of -24% (95% CI: -54 to 7%) (p = 0.1103) (Fig. 4B). Changes in UACR in spot 
urine were similar to those in the first-morning-void urine. 
 
eGFR 
The time course of mean eGFR is shown in Fig. 3C. The mean change in eGFR level from baseline to the 
last visit was -4.0 (95% CI: -6.7 to -1.2) in the placebo group (n = 22) and -0.2 (95% CI: -2.2 to 1.7) in 
the topiroxostat group (n = 43) with a between-group difference of 3.7 (95% CI: 0.4 to 7.1) (p = 0.0303) 
(Fig. 4C). The eGFR declined in the placebo group, but was unchanged in the topiroxostat group. 





The time course of mean SUA is shown in Fig. 3D. The mean change in SUA from baseline to the last 
visit was -0.20 (95% CI: -0.58 to 0.18) in the placebo group (n = 22) and -2.94 (95% CI: -3.21 to -2.66) in 
the topiroxostat group (n = 43) with a between-group difference of -2.74 (95% CI: -3.20 to -2.27) (p < 
0.0001) (Fig. 4D). SUA did not change in the placebo group, but decreased in the topiroxostat group. The 
difference was statistically significant. 
The numbers of patients who had normalized SUA (> 6.0 mg/dL at baseline, and ≤ 6.0mg/dL at the last 




Adverse events occurred in 11 patients (50.0%) in the placebo group and 32 patients (74.4%) in the 
topiroxostat group. No between-group difference was observed for the incidence of adverse events 
(Fisher's exact test; p = 0.0585). No deaths were observed in either group during the study period. Serious 
adverse events were observed in 3 patients (3 cases) in the topiroxostat group and 2 patients (3 cases) in 
the placebo group. The breakdown is as follows: “Diabetic retinopathy (n = 2)” and “colon cancer (n = 1)” 
in the topiroxostat group, and “lumbar spinal stenosis (n = 1),” “intervertebral disc disorder (n = 1),” and 
“hepatocellular carcinoma (n = 1)” in the placebo group. A causal relationship of serious adverse events 
with the investigational drug was denied. 
Four patients in the placebo group and 1 patient in the topiroxostat group withdrew from this study due to 
adverse events. The breakdown is as follows: “intervertebral disc disorder and lumbar spinal stenosis (n = 
1),” “hyperglycaemia (n= 2),” and “hepatocellular carcinoma (n = 1)” in the placebo group, and “colon 
cancer (n = 1)” in the topiroxostat group. 
“Arthritis (n = 1)” and “gouty arthritis (n = 1)” were reported as adverse drug reactions in the placebo 
group, and “alanine aminotransferase increase (n = 1)” and “aspartate aminotransferase increase (n = 1)” 
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were reported as adverse drug reactions in the topiroxostat group (Table 2). 
 
Control of complications 
The time course of the mean values of glycosylated hemoglobin (HbA1c), systolic blood pressure (SBP), 
diastolic blood pressure (DBP), LDL, and high-density lipoprotein-cholesterol (HDL) is shown in Fig. 5. 
The treatment of diabetes, dyslipidemia, and hypertension in each study group remained the same and the 
diseases were well controlled during the entire study period. There were no significant differences in SBP, 
DBP, LDL, or HDL .However, the mean change in HbA1c level from baseline to the last visit was 0.48 
(95% CI: 0.19 to 0.77) in the placebo group (n = 21) and 0.08 (95% CI: -0.12 to 0.29) in the topiroxostat 
group (n = 43) with a between-group difference of -0.40 (95% CI: -0.76 to -0.04) (p = 0.0303) analyzed 
by the ANCOVA model; the covariate was baseline HbA1c. To examine whether increase in HbA1c 
affects decrease in eGFR, we performed simple linear regression analysis. As a result, the regression 
equation: eGFR change = -1.34789 -0.66108 * HbA1c change, and coefficient of determination: 0.0048, 
were obtained. Therefore, increase in HbA1c did not affect decrease in eGFR. 
 
Discussion 
This is the first double blind study involving topiroxostat for patients with diabetic nephropathy with 
microalbuminuria. We showed that a stepwise increase of topiroxostat to a dose of 160 mg/day effectively 
reduced the SUA level in patients with diabetic nephropathy combined with hyperuricemia. Adverse drug 
reactions observed in this study were only mild elevations of AST and ALT, which had been reported in 
previous studies [9] in one patient. Furthermore, in the topiroxostat group, no patients had onset of gout 
attacks which were often observed under the strict control of SUA. 
Concerning albuminuria, UACR levels tended to increase in the placebo group, while they did not tend to 
increase in the topiroxostat group. However, no statistically significant difference was observed in the 
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change in UACR between the topiroxostat group and the placebo group. We referred to a clinical study of 
topiroxostat in patients with hyperuricemic stage 3 chronic kidney disease [12]. In this study, the standard 
deviation of change in UACR in the topiroxostat group was 0.297. Meanwhile, in the UPWARD study, 
the standard deviation of change in UACR in the topiroxostat group was 0.557. These results might 
support the heterogeneousness of the inpatients with albuminuria examined in this study. Several studies 
suggest that hyperuricemia may be a factor of the progress of albuminuria in diabetic nephropathy [14, 
15] and that XOR inhibitors may reduce albuminuria [16-18]. On the other hand, there were few studies 
that showed uricosuric agents without XOR inhibitory potency may reduce albuminuria. The relationship 
between XOR activity and albuminuria should be examined in the future. 
As for eGFR, we found a significant difference in eGFR changes between the topiroxostat group and the 
placebo group. Interestingly, although enrollment of eligible patients, randomization, and blinding were 
conducted properly, the eGFR in the placebo group declined 6% within half a year. It was reported that 
the rate of eGFR decline in diabetic patients with microalbuminuria is about 1.0% to 2.0% per year [19, 
20]. Hence eGFR of patients in this study seemed to decline rapidly. Diabetes, hypertension [21-26], and 
dyslipidemia [27] are well known as risk factors for renal function deterioration. Patients in this study had 
these multiple risk factors, however, these patient’s complications were well controlled, and their 
biomarkers did not fluctuate sharply. In particular, almost all patients received RAS blockers constantly 
without changing dosage during the study period. The only significant difference of markers between the 
placebo group patients and the topiroxostat group patients was SUA level. 
Recent studies have shown that elevated SUA levels may be associated with the faster progression of 
diabetic kidney disease [28-30]. The present data indicate that these past findings may be applicable to 
early stage diabetic nephropathy.  
Although UA lowering therapy for preventing and slowing kidney disease progression has not been 
established, the result of this study suggests that appropriate management of hyperuricemia at an early 
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stage of diabetic kidney disease is likely to be important for renal protection.  
Furthermore, XOR activity is connected with endothelial dysfunction via inflammation and oxidative 
stress [31, 32], and XOR in diabetic patients is found to be activated [33, 34], as previously reported. 
Since XOR inhibitors reduce the production of reactive oxygen species [35, 36] in addition to lowering of 
the UA level, topiroxostat has the possibility to provide renal protection through XOR inhibition.  
There are several limitations to this study. The first point is that this study is just a pilot study involving a 
small number of patients and only half a year of observation. Therefore, robustness and reproducibility 
may be insufficient. Large-scale and long-term observation may be necessary to confirm whether changes 
in eGFR obtained as a result of this study are general facts. In addition, we could not find a statistically 
significant difference in UACR. The second point is that patients included in this study are early stage 
diabetic nephropathy patients with microalbuminuria. Similar intervention studies for patients with overt 
albuminuria with UACR > 300 or those with even lower renal function, e.g. GFR of 30 or less, are 
considered as a future task in progression of nephropathy. Recently a study involving hyperuricemic 
patients with diabetic nephropathy and overt proteinuria was reported [37] [38]. In this report, 
topiroxostat had a steady anti-albuminuric effect in patients with type 2 diabetes and overt proteinuria 
who were at high risk of progressive diabetic nephropathy. This investigation might be an advance in the 
evaluation of the potential of topiroxostat to reduce albuminuria. The third point is that this study targeted 
only patients diagnosed with gout or hyperuricemia. Even if topiroxostat has a renal protective effect in 
case of diabetic nephropathy, it is unknown whether such effect is completely independent of reduced uric 
acid level. We should confirm this with a study in diabetic nephropathy patients having normal uric acid 
level. 
In conclusion, the results of this study demonstrated that treatment with topiroxostat effectively reduced 
the SUA levels with good tolerability and safety in hyperuricemic patients with early diabetic 
nephropathy. Although further clinical studies are necessary to validate this potential, topiroxostat appears 
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